BRIEF-Swedish Orphan Biovitrum says EMA validates Alprolix marketing authorisation ap
 

BRIEF-Swedish Orphan Biovitrum says EMA validates Alprolix marketing authorisation application
* The European Medicines Agency (EMA) has accepted the companies' Marketing Authorisation Application (MAA) of Alprolix (rFIXFc), a recombinant factor IX Fc fusion protein product candidate for the treatment of haemophilia B.http://i0.wp.com/reuters.us.feedspor...f?resize=1%2C1
http://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/reut...2o:V_sGLiPBpWU http://feeds.feedburner.com/~ff/reut...2o:F7zBnMyn0Lo
http://feeds.feedburner.com/~r/reute...~4/55p5d9tVbiY